home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409c.zip
/
M9490316.TXT
< prev
next >
Wrap
Text File
|
1994-09-19
|
2KB
|
36 lines
Document 0316
DOCN M9490316
TI Secondary bacterial infections in HIV-infected patients: an alternative
ambulatory outpatient treatment utilizing intravenous cefotaxime.
DT 9411
AU Morales JO; Von Behren L; Ashford Presbyterian Community Hospital, San
Juan, Puerto Rico; 00907.
SO Am J Med. 1994 Aug 15;97(2A):9-13. Unique Identifier : AIDSLINE
MED/94337804
AB The purpose of this study was to determine the safety and efficacy of
home intravenous antibiotic therapy in treating secondary bacterial
infections in patients infected with the human immunodeficiency virus
(HIV). This study was a subset analysis of 22 patients with HIV,
enrolled in two centers of a multicenter, open-label, prospective study.
When necessary, patients were stabilized as inpatients, followed by home
therapy. Enrolled patients had diagnoses of pneumonia, skin and
soft-tissue infections, bacteremia/septicemia, or other infections
requiring parenteral therapy. A third-generation cephalosporin,
cefotaxime, 1-2 g every 8 hours, was delivered intravenously using an
ambulatory delivery system (ADS). Home therapy with cefotaxime/ADS
produced a clinical response rate of 95% and bacteriologic response of
88.2%. The requirement for and duration of inpatient therapy was
markedly reduced compared with diagnosis-related group (DRG) allotments.
In conclusion, home intravenous antibiotic therapy with cefotaxime in
patients infected with HIV is effective and safe. It may improve quality
of life by reducing the length of hospital stay.
DE Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Bacterial
Infections/COMPLICATIONS/*DRUG THERAPY Cefotaxime/*ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS Female *Home Care Services Human *Infusion
Pumps Length of Stay Male Prospective Studies CLINICAL TRIAL
JOURNAL ARTICLE MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).